MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA – Get Free Report) shares traded up 15.7% on Thursday . The stock traded as high as $2.68 and last traded at $2.43. 4,685,065 shares traded hands during trading, an increase of 99% from the average session volume of 2,353,060 shares. The stock had previously closed at $2.10.
MIRA Pharmaceuticals Trading Down 10.7 %
The company has a 50 day moving average price of $1.11 and a 200 day moving average price of $1.03. The firm has a market cap of $32.07 million and a PE ratio of -3.24.
MIRA Pharmaceuticals (NASDAQ:MIRA – Get Free Report) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). As a group, equities research analysts anticipate that MIRA Pharmaceuticals, Inc. will post -0.62 earnings per share for the current fiscal year.
Hedge Funds Weigh In On MIRA Pharmaceuticals
About MIRA Pharmaceuticals
MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.
Featured Articles
- Five stocks we like better than MIRA Pharmaceuticals
- Market Cap Calculator: How to Calculate Market Cap
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Canada Bond Market Holiday: How to Invest and Trade
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- High Flyers: 3 Natural Gas Stocks for March 2022
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for MIRA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MIRA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.